271 related articles for article (PubMed ID: 19340297)
1. CDKN1C (p57) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells.
Yang X; Karuturi RK; Sun F; Aau M; Yu K; Shao R; Miller LD; Tan PB; Yu Q
PLoS One; 2009; 4(4):e5011. PubMed ID: 19340297
[TBL] [Abstract][Full Text] [Related]
2. Estrogen-mediated epigenetic repression of the imprinted gene cyclin-dependent kinase inhibitor 1C in breast cancer cells.
Rodriguez BA; Weng YI; Liu TM; Zuo T; Hsu PY; Lin CH; Cheng AL; Cui H; Yan PS; Huang TH
Carcinogenesis; 2011 Jun; 32(6):812-21. PubMed ID: 21304052
[TBL] [Abstract][Full Text] [Related]
3. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer.
Ren G; Baritaki S; Marathe H; Feng J; Park S; Beach S; Bazeley PS; Beshir AB; Fenteany G; Mehra R; Daignault S; Al-Mulla F; Keller E; Bonavida B; de la Serna I; Yeung KC
Cancer Res; 2012 Jun; 72(12):3091-104. PubMed ID: 22505648
[TBL] [Abstract][Full Text] [Related]
4. Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells.
Sun F; Chan E; Wu Z; Yang X; Marquez VE; Yu Q
Mol Cancer Ther; 2009 Dec; 8(12):3191-202. PubMed ID: 19934278
[TBL] [Abstract][Full Text] [Related]
5. CDYL promotes the chemoresistance of small cell lung cancer by regulating H3K27 trimethylation at the CDKN1C promoter.
Qiu Z; Zhu W; Meng H; Tong L; Li X; Luo P; Yi L; Zhang X; Guo L; Wei T; Zhang J
Theranostics; 2019; 9(16):4717-4729. PubMed ID: 31367252
[No Abstract] [Full Text] [Related]
6. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation.
Kondo Y; Shen L; Cheng AS; Ahmed S; Boumber Y; Charo C; Yamochi T; Urano T; Furukawa K; Kwabi-Addo B; Gold DL; Sekido Y; Huang TH; Issa JP
Nat Genet; 2008 Jun; 40(6):741-50. PubMed ID: 18488029
[TBL] [Abstract][Full Text] [Related]
7. Long noncoding RNA TALNEC2 plays an oncogenic role in breast cancer by binding to EZH2 to target p57
Qiao E; Chen D; Li Q; Feng W; Yu X; Zhang X; Xia L; Jin J; Yang H
J Cell Biochem; 2019 Mar; 120(3):3978-3988. PubMed ID: 30378143
[TBL] [Abstract][Full Text] [Related]
8. A cross-talk between DNA methylation and H3 lysine 9 dimethylation at the KvDMR1 region controls the induction of Cdkn1c in muscle cells.
Andresini O; Ciotti A; Rossi MN; Battistelli C; Carbone M; Maione R
Epigenetics; 2016 Nov; 11(11):791-803. PubMed ID: 27611768
[TBL] [Abstract][Full Text] [Related]
9. EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers.
Au SL; Wong CC; Lee JM; Wong CM; Ng IO
PLoS One; 2013; 8(6):e68226. PubMed ID: 23826380
[TBL] [Abstract][Full Text] [Related]
10. EZH2 methyltransferase and H3K27 methylation in breast cancer.
Yoo KH; Hennighausen L
Int J Biol Sci; 2012; 8(1):59-65. PubMed ID: 22211105
[TBL] [Abstract][Full Text] [Related]
11. Repression of E-cadherin by the polycomb group protein EZH2 in cancer.
Cao Q; Yu J; Dhanasekaran SM; Kim JH; Mani RS; Tomlins SA; Mehra R; Laxman B; Cao X; Yu J; Kleer CG; Varambally S; Chinnaiyan AM
Oncogene; 2008 Dec; 27(58):7274-84. PubMed ID: 18806826
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
[TBL] [Abstract][Full Text] [Related]
13. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.
Fiskus W; Wang Y; Sreekumar A; Buckley KM; Shi H; Jillella A; Ustun C; Rao R; Fernandez P; Chen J; Balusu R; Koul S; Atadja P; Marquez VE; Bhalla KN
Blood; 2009 Sep; 114(13):2733-43. PubMed ID: 19638619
[TBL] [Abstract][Full Text] [Related]
14. Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation.
Fujii S; Ito K; Ito Y; Ochiai A
J Biol Chem; 2008 Jun; 283(25):17324-32. PubMed ID: 18430739
[TBL] [Abstract][Full Text] [Related]
15. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic repression of SATB1 by polycomb group protein EZH2 in epithelial cells.
Lei L; Lu L; Xiang L; Xue-song W; De-pei L; Chih-chuan L
Chin Med Sci J; 2010 Dec; 25(4):199-205. PubMed ID: 21232178
[TBL] [Abstract][Full Text] [Related]
17. Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2.
Chen S; Bohrer LR; Rai AN; Pan Y; Gan L; Zhou X; Bagchi A; Simon JA; Huang H
Nat Cell Biol; 2010 Nov; 12(11):1108-14. PubMed ID: 20935635
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer.
Chen H; Tu SW; Hsieh JT
J Biol Chem; 2005 Jun; 280(23):22437-44. PubMed ID: 15817459
[TBL] [Abstract][Full Text] [Related]
19. MEK-ERK pathway regulates EZH2 overexpression in association with aggressive breast cancer subtypes.
Fujii S; Tokita K; Wada N; Ito K; Yamauchi C; Ito Y; Ochiai A
Oncogene; 2011 Sep; 30(39):4118-28. PubMed ID: 21499305
[TBL] [Abstract][Full Text] [Related]
20. EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer.
Pietersen AM; Horlings HM; Hauptmann M; Langerød A; Ajouaou A; Cornelissen-Steijger P; Wessels LF; Jonkers J; van de Vijver MJ; van Lohuizen M
Breast Cancer Res; 2008; 10(6):R109. PubMed ID: 19099573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]